D5 dopamine receptor knockout mice and hypertension

Journal of Receptors and Signal Transduction

Volumn 24, Issue 3, 2004, Pages 149-164

  Yang, Zhiwei ^a   Sibley, David R ^b   Jose, Pedro A ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

Dopamine receptor genes; G protein effector complex; Hypertension; Sodium transport

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; DOPAMINE 5 RECEPTOR; G PROTEIN COUPLED RECEPTOR KINASE; G PROTEIN COUPLED RECEPTOR KINASE 4; GUANINE NUCLEOTIDE BINDING PROTEIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; OXYTOCIN RECEPTOR; SERINE; UNCLASSIFIED DRUG; VASOPRESSIN V1 RECEPTOR; DRD5 PROTEIN, MOUSE; GLUTAMATE RECEPTOR; VASOPRESSIN RECEPTOR;

ADRENERGIC SYSTEM; ANIMAL MODEL; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CENTRAL NERVOUS SYSTEM; CONFERENCE PAPER; DISEASE ASSOCIATION; DOPAMINE METABOLISM; ESSENTIAL HYPERTENSION; HEREDITARY HYPERTENSION; HUMAN; HYPERTENSION; INTESTINE; KIDNEY; NONHUMAN; RAT; SODIUM TRANSPORT; ANIMAL; GENETICS; MOUSE; MOUSE MUTANT; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

ANIMALIA; MAMMALIA; RODENTIA;

ANIMALS; BLOOD PRESSURE; HYPERTENSION; MICE; MICE, KNOCKOUT; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D5; RECEPTORS, GABA-A; RECEPTORS, GLUTAMATE; RECEPTORS, OXYTOCIN; RECEPTORS, VASOPRESSIN; SYMPATHETIC NERVOUS SYSTEM;

EID: 16644396623     PISSN: 10799893     EISSN: 15324281     Source Type: Journal    
DOI: 10.1081/RRS-200029971     Document Type: Conference Paper

References (126)

1. Sibley DR, Monsma FJ Jr. Molecular biology of dopamine receptors. Trends Pharmacol Sci 1992; 13(2):61-69.
2. Glickstein SB, Schmauss C. Dopamine receptor functions: lessons from knockout mice. Pharmacol Ther 2001; 91(1):63-83.
3. Ferro A. Renal dopamine receptors and hypertension. J Hypertens 2003; 21(1):37-38.
4. Hussain T, Lokhandwala MF. Renal dopamine receptor function in hypertension. Hypertension 1998; 32(2):187-197.
5. Jose PA, Eisner GM, Felder RA. Role of dopamine receptors in the kidney in the regulation of blood pressure. Curr Opin Nephrol Hypertens 2002; 11(1):87-92.
6. Jose PA, Eisner GM, Felder RA. The renal dopamine receptors in health and hypertension. Pharmacol Ther 1998; 80(2):149-182.
7. Jose PA, Eisner GM, Felder RA. Dopaminergic mechanisms in the development of hypertension. In: McCarty R, Blizard DA, Chevalier RI, eds. Development of the Hypertensive Phenotype: Basic and Clinical Studies, In Handbook of Hypertension 19. Amsterdam: Elsevier Science, 1999:1-44.
8. Jose PA, Eisner GM, Felder RA. Dopamine receptor-coupling defect in hypertension. Curr Hypertens Rep 2002; 4(3):237-244.
9. 1 dopamine receptor signaling defect in spontaneous hypertension. Acta Physiol Scand 2000; 168(1):245-250.
10. Kohout TA, Lefkowitz RJ. Regulation of G protein-coupled receptor kinases and arrestins during receptor desensitization. Mol Pharmacol 2003; 63(1):9-18.
11. Sibley DR. New insights into dopaminergic receptor function using antisense and genetically altered animals. Annu Rev Pharmacol Toxicol 1999; 39:313-341.
12. +-ATPase activity is lacking in Dahl salt-sensitive rats. Hypertension 1993; 21(6 Pt 1):767-771.
13. +-ATPase in kidney of spontaneously hypertensive rats. Clin Exp Hypertens 1996; 18(7):963-974.
14. - cotransporter in rabbits and normotensive rats but not in spontaneously hypertensive rats. Kidney Int 2000; 57(2):534-543.
15. Horiuchi A, Albrecht FE, Eisner GM, Jose PA, Felder RA. Renal dopamine receptors and pre- and post-cAMP mediated sodium transport defect in the spontaneously hypertensive rat. Am J Physiol 1992; 263(6 Pt 2):F1105-F1111.
16. Eisner GM, Asico LD, Albrecht FE, Jose PA. Dopamine and diltiazem-induced natriuresis in the spontaneously hypertensive rat. Am J Physiol 1997; 273(1 Pt 2):R317-R323.
17. Grossman E, Hoffman A, Tamrat M, Armando I, Keiser HR, Goldstein DS. Endogenous dopa and dopamine responses to dietary salt loading in salt-sensitive rats. J Hypertens 1991; 9(3):259-263.
18. Saito I, Itsuji S, Takeshita E, Kawabe H, Nishino M, Wainai H, Hasegawa C, Saruta T, Nagano S, Sekihara T. Increased urinary dopamine excretion in young patients with essential hypertension. Clin Exp Hypertens 1994; 16(1):29-39.
19. Saito I, Takeshita E, Saruta T, Nagano S, Sekihara T. Urinary dopamine excretion in normotensive subjects with or without family history of hypertension. J Hypertens 1986; 4(1):57-60.
20. Racz K, Kuchel O, Buu NT, Tenneson S. Peripheral dopamine synthesis and metabolism in spontaneously hypertensive rats. Circ Res 1985; 57(6):889-897.
21. + exchanger interactions in the kidney in hypertension. Hypertension 2000; 36(3):395-399.
22. Li XX, Xu J, Zheng S, Albrecht FE, Robillard JE, Eisner GM, Jose PA. D(1) dopamine receptor regulation of NHE3 during development in spontaneously hypertensive rats. Am J Physiol Regul Integr Comp Physiol 2001; 280(6):R1650-R1656.
23. q/11 proteins in spontaneously hypertensive rats. Am J Physiol 1997; 272(3 Pt 2):F339-F346.
24. Wiederkehr MR, Di Sole F, Collazo R, Quinones H, Fan L, Murer H, Helmle-Kolb C, Moe OW. Characterization of acute inhibition of Na/H exchanger NHE-3 by dopamine in opossum kidney cells. Kidney Int 2001; 59(1):197-209.
25. Michel MC, Farke W, Erdbrugger W, Philipp T, Brodde OE. Ontogenesis of sympathetic responsiveness in spontaneously hypertensive rats. II. Renal G proteins in male and female rats. Hypertension 1994; 23(5):653-658.
26. Felder RA, Kinoshita S, Ohbu K, Mouradian MM, Sibley DR, Monsma FJ Jr, Minowa T, Minowa MT, Canessa LM, Jose PA. Organ specificity of the dopamine1 receptor/adenylyl cyclase coupling defect in spontaneously hypertensive rats. Am J Physiol 1993; 264(4 Pt 2):R726-R732.
27. Chen C, Beach RE, Lokhandwala MF. Dopamine fails to inhibit renal tubular sodium pump in hypertensive rats. Hypertension 1993; 21(3):364-372.
28. Sidhu A, Vachvanichsanong P, Jose PA, Felder RA. Persistent defective coupling of dopamine-1 receptors to G proteins after solubilization from kidney proximal tubules of hypertensive rats. J Clin Invest 1992; 89(3):789-793.
29. Sela S, White BH, Uh M, Kimura K, Patel S, Sidhu A. Dysfunctional D1A receptor-G-protein coupling in proximal tubules of spontaneously hypertensive rats is not due to abnormal G-proteins. J Hypertens 1997; 15(3):259-267.
30. +-coupled ion carriers in isolated mammalian kidney epithelial cells: regulation by protein kinase C. Can J Physiol Pharmacol 1999; 77(5):305-319.
31. Albrecht FE, Drago J, Felder RA, Printz MP, Eisner GM, Robillard JE, Sibley DR, Westphal HJ, Jose PA. Role of the D1A dopamine receptor in the pathogenesis of genetic hypertension. J Clin Invest 1996; 97(10):2283-2288.
32. + exchanger in spontaneously hypertensive rats. Am J Physiol 1991; 261(3 Pt 2):F526-F536.
33. Ohbu K, Felder RA. Nephron specificity of dopamine receptor-adenylyl cyclase defect in spontaneous hypertension. Am J Physiol 1993; 264(2 Pt 2):F274-F279.
34. Ohbu K, Kaskel FJ, Kinoshita S, Felder RA. Dopamine-1 receptors in the proximal convoluted tubule of Dahl rats: defective coupling to adenylate cyclase. Am J Physiol 1995; 268(1 Pt 2):R231-R235.
35. Bughi S, Horton R, Antonipillai I, Manoogian C, Ehrlich L, Nadler J. Comparison of dopamine and fenoldopam effects on renal blood flow and prostacyclin excretion in normal and essential hypertensive subjects. J Clin Endocrinol Metab 1989; 69(6):1116-1121.
36. de Vries PA, Navis G, de Jong PE, de Zeeuw D, Kluppel CA. Impaired renal vascular response to a D1-like receptor agonist but not to an ACE inhibitor in conscious spontaneously hypertensive rats. J Cardiovasc Pharmacol 1999; 34(2):191-198.
37. Chatziantoniou C, Ruan X, Arendshorst WJ. Defective G protein activation of the cAMP pathway in rat kidney during genetic hypertension. Proc Natl Acad Sci USA 1995; 92(7):2924-2928.
38. Murphy MB. Dopamine: a role in the pathogenesis and treatment of hypertension. J Hum Hypertens 2000; 14(Suppl 1):S47-S50.
39. O'Connell DP, Ragsdale NV, Boyd DG, Felder RA, Carey RM. Differential human renal tubular responses to dopamine type 1 receptor stimulation are determined by blood pressure status. Hypertension 1997; 29(1 Pt 1):115-122.
40. Sanada H, Jose PA, Hazen-Martin D, Yu PY, Xu J, Bruns DE, Phipps J, Carey RM, Felder RA. Dopamine-1 receptor coupling defect in renal proximal tubule cells in hypertension. Hypertension 1999; 33(4):1036-1042.
41. Masuzawa K, Matsuda T, Asano M. Decreased arterial responsiveness to multiple cyclic AMP-generating receptor agonists in spontaneously hypertensive rats. Br J Pharmacol 1989; 96(1):227-235.
42. Haberle DA, Konigbauer B. Inhibition of tubuloglomerular feedback by the D1 agonist fenoldopam in chronically salt-loaded rats. J Physiol 1991; 441:23-34.
43. Yarnaguchi I, Jose PA, Mouradian MM, Canessa LM, Monsma FJ Jr, Sibley DR, Takeyasu K, Felder RA. Expression of dopamine D1A receptor gene in proximal tubule of rat kidneys. Am J Physiol 1993; 264(2 Pt 2):F280-F285.
44. Yao LP, Huque E, Baraniuk JN, Felder RA, Carey RM, Jose PA. Dopamine-1 receptor subtype (D1A and D1B) expression in microdissected rat nephron segments. Pediatr Res 1997; 41:286A.
45. O'Connell DP, Botkin SJ, Ramos SI, Sibley DR, Ariano MA, Felder RA, Carey RM. Localization of dopamine D1A receptor protein in rat kidneys. Am J Physiol 1995; 268(6 Pt 2):F1185-1197.
46. Sidhu A, Kumar U, Uh M, Patel S. Diminished expression of renal dopamine D1A receptors in the kidney inner medulla of the spontaneously hypertensive rat. J Hypertens 1998; 16(5):601-608.
47. Sanada H, Xu J, Jose PA, Felder RA. Differential expression and regulation of D1 and D5 receptor function in human kidney. FASEB J 1999; 13:A462.
48. Felder RA, Sanada H, Xu J, Yu PY, Wang Z, Watanabe H, Asico LD, Wang W, Zheng S, Yamaguchi I, Williams SM, Gainer J, Brown NJ, Hazen-Martin D, Wong LJ, Robillard JE, Carey RM, Eisner GM, Jose PA. G protein-coupled receptor kinase 4 gene variants in human essential hypertension. Proc Natl Acad Sci USA 2002; 99(6):3872-3877.
49. Amenta F, Barili P, Bronzetti E, Felici L, Mignini F, Ricci A. Localization of dopamine receptor subtypes in systemic arteries. Clin Exp Hypertens 2000; 22(3):277-288.
50. Yu P, Hopfer U, Felder RA, Jose PA. Increased serine-phosphorylation of the D1 receptor in renal proximal tubule cells in hypertension. Am J Hypertens 2000; 13:12A-13A.
51. Bek M, Asico LD, Eisner GM, Sibley DR, Jose PA. Non-N-methyl D-aspartate receptors are involved in the hypertension of D5 receptor knockout mice. Hypertension 2000; 36:726.
52. Hollon TR, Bek MJ, Lachowicz JE, Ariano MA, Mezey E, Ramachandran R, Wersinger SR, Soares-da-Silva P, Liu ZF, Grinberg A, Drago J, Young WS III, Westphal H, Jose PA, Sibley DR. Mice lacking D5 dopamine receptors have increased sympathetic tone and are hypertensive. J Neurosci 2002; 22(24):10801-10810.
53. Krushkal J, Ferrell R, Mockrin SC, Turner ST, Sing CF, Boerwinkle E. Genome-wide linkage analyses of systolic blood pressure using highly discordant siblings. Circulation 1999; 99(1):1407-1410.
54. Kren V, Pravenec M, Lu S, Krenova D, Wang JM, Wang N, Merriouns T, Wong A, St Lezin E, Lau D, Szpirer C, Szpirer J, Kurtz TW. Genetic isolation of a region of chromosome 8 that exerts major effects on blood pressure and cardiac mass in the spontaneously hypertensive rat. J Clin Invest 1997; 99(4):577-581.
55. Sato M, Soma M, Nakayama T, Kanmatsuse K. Dopamine D1 receptor gene polymorphism is associated with essential hypertension. Hypertension 2000; 36(2):183-186.
56. Watanabe H, Xu J, Bengra C, Jose PA, Felder RA. Desensitization of human renal D1 dopamine receptors by G protein-coupled receptor kinase 4. Kidney Int 2002; 62(3):790-798.
57. Gros R, Chorazyczewski J, Meek MD, Benovic JL, Ferguson SS, Feldman RD. G-Protein-coupled receptor kinase activity in hypertension: increased vascular and lymphocyte G-protein receptor kinase-2 protein expression. Hypertension 2000; 35(1 Pt 1):38-42.
58. Ishizaka N, Alexander RW, Laursen JB, Kai H, Fukui T, Oppermann M, Lefkowitz RJ, Lyons PR, Griendling KK. G protein-coupled receptor kinase 5 in cultured vascular smooth muscle cells and rat aorta. Regulation by angiotensin II and hypertension. J Biol Chem 1997; 272(51):32482-32488.
59. Yu P, Asico LD, Eisner GM, Hopfer U, Felder RA, Jose PA. Renal protein phosphatase 2A activity and spontaneous hypertension in rats. Hypertension 2000; 36(6):1053-1058.
60. Sunahara RK, Guan HC, O'Dowd BF, Seeman P, Laurier LG, Ng G, George SR, Torchia J, Van Tol HH, Niznik HB. Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1. Nature 1991; 350(6319):614-619.
61. Tiberi M, Caron MG. High agonist-independent activity is a distinguishing feature of the dopamine D1B receptor subtype. J Biol Chem 1994; 269(45):27925-27931.
62. Ginn DI, Baptista CA, Alam KY, Deng AY, Dene H, Le H, Kurtz TW, Rapp JP. Genetic analysis of alpha 2-adrenergic receptors and blood pressure using Dahl salt-sensitive rats. J Hypertens 1994; 12(4):357-365.
63. Burgess LH, Monsma FJ Jr, Shen Y, Jose PA, Sibley DR. Further characterization of D1A and D1B dopamine receptors in rat kidney. Soc Neurosci Abstracts 1993; 19:75.
64. Casari G, Barlassina C, Cusi D, Zagato L, Muirhead R, Righetti M, Nembri P, Amar K, Gatti M, Macciardi F, Binelli G, Bianchi G. Association of the α-adducin locus with essential hypertension. Hypertension 1995; 25(3):320-326.
65. Allayee H, de Bruin TW, Michelle Dominguez K, Cheng LS, Ipp E, Cantor RM, Krass KL, Keulen ET, Aouizerat BE, Lusis AJ, Rotter JI. Genome scan for blood pressure in Dutch dyslipidemic families reveals linkage to a locus on chromosome 4p. Hypertension 2001; 38(4):773-778.
66. Cravchik A, Gejman PV. Functional analysis of the human D5 dopamine receptor missense and nonsense variants: differences in dopamine binding affinities. Pharmacogenetics 1999; 9(2):199-206.
67. Holmes A, Hollon TR, Gleason TC, Liu Z, Dreiling J, Sibley DR, Crawley JN. Behavioral characterization of dopamine D5 receptor null mutant mice. Behav Neurosci 2001; 115(5):1129-1144.
68. 1A dopamine receptors. Proc Natl Acad Sci USA 1994; 91(26):12564-12568.
69. Hartner A, Cordasic N, Klanke B, Veelken R, Hilgers KF. Strain differences in the development of hypertension and glomerular lesions induced by deoxycorticosterone acetate salt in mice. Nephrol Dial Transplant 2003; 18(10):1999-2004.
70. Fujii M, Kara H, Meng W, Vonsattel JP, Huang Z, Moskowitz MA. Strain-related differences in susceptibility to transient forebrain ischemia in SV-129 and C57black/6 mice. Stroke 1997; 28(9):1805-1810.
71. DiBona GF. Sympathetic nervous system and the kidney in hypertension. Curr Opin Nephrol Hypertens 2002; 11(2):197-200.
72. Tuncel M, Augustyniak R, Zhang W, Toto RD, Victor RG. Sympathetic nervous system function in renal hypertension. Curr Hypertens Rep 2002; 4(3):229-236.
73. Brooks VL, Scrogin KE, McKeogh DF. The interaction of angiotensin II and osmolality in the generation of sympathetic tone during changes in dietary salt intake: an hypothesis. Ann N Y Acad Sci 2001; 940:380-394.
74. Wyss JM, Carlson SH. The role of the nervous system in hypertension. Curr Hypertens Rep 2001; 3(3):255-262.
75. Luo M, Fink GD, Lookingland KJ, Morris JA, Galligan JJ. Impaired function of α2 adrenergic autoreceptors on sympathetic nerves associated with mesenteric arteries and veins in DOCA-salt hypertension. Am J Physiol Heart Circ Physiol 2003; Dec 11 [Epub ahead of print].
76. Hinojosa-Laborde C, Chapa I, Lange D, Haywood JR. Gender differences in sympathetic nervous system regulation. Clin Exp Pharmacol Physiol 1999; 26(2):122-126.
77. Lohmeier TE. The sympathetic nervous system and long-term blood pressure regulation. Am J Hypertens 2001; 14:147S-154S.
78. Veerasingham SJ, Raizada MK. Brain renin-angiotensin system dysfunction in hypertension: recent advances and perspectives. Br J Pharmacol 2003; 139(2):191-202.
79. Dahmer MK, Senogles SE. Dopaminergic inhibition of catecholamine secretion from chromaffin cells: evidence that inhibition is mediated by D4 and D5 dopamine receptors. J Neurochem 1996; 66(1):222-232.
80. Dampney RA, Horiuchi J, Tagawa T, Fontes MA, Potts PD, Polson JW. Medullary and supramedullary mechanisms regulating sympathetic vasomotor tone. Acta Physiol Scand 2003; 177(3):209-218.
81. D'Amico M, Berrino L, Pizzirusso A, de Novellis V, Rossi F. Opposing effects on blood pressure following the activation of metabotropic and ionotropic glutamate receptors in raphe obscurus in the anaesthetized rat. Naunyn Schmiedebergs Arch Pharmacol 1996; 353(3):302-305.
82. Ito S, Komatsu K, Tsukamoto K, Sved AF. Excitatory amino acids in the rostral ventrolateral medulla support blood pressure in spontaneously hypertensive rats. Hypertension 2000; 35(1 Pt 2):413-417.
83. Dingledine R, Borges K, Bowie D, Traynelis SF. The glutamate receptor ion channels. Pharmacol Rev 1999; 51(1):7-61.
84. Zhang J, Abdel-Rahman AA. The hypotensive action of rilmenidine is dependent on functional N-methyl-D-aspartate receptor in the rostral ventrolateral medulla of conscious spontaneously hypertensive rats. J Pharmacol Exp Ther 2002; 303(1):204-210.
85. Lin JC, Tsao WL, Wang Y. Cardiovascular effects of NMDA in the RVLM of spontaneously hypertensive rats. Brain Res Bull 1995; 37(3):289-294.
86. Maiorov DN, Krenz NR, Krassioukov AV, Weaver LC. Role of spinal NMDA and AMPA receptors in episodic hypertension in conscious spinal rats. Am J Physiol 1997; 273(3 Pt 2):H1266-H1274.
87. Butcher KS, Cechetto DF. Receptors in lateral hypothalamic area involved in insular cortex sympathetic responses. Am J Physiol 1998; 275(2 Pt 2):H689-H696.
88. Chen K, Hernandez YM, Dretchen KL, Gillis RA. Intravenous NBQX inhibits spontaneously occurring sympathetic nerve activity and reduces blood pressure in cats. Eur J Pharmacol 1994; 252(2):155-160.
89. Araujo GC, Lopes OU, Campos RR. Importance of glycinergic and glutamatergic synapses within the rostral ventrolateral medulla for blood pressure regulation in conscious rats. Hypertension 1999; 34(4 Pt 2):752-755.
90. Amenta F, Ricci A, Rossodivita I, Avola R, Tayebati SK. The dopaminergic system in hypertension. Clin Exp Hypertens 2001; 23(1-2):15-24.
91. Lee FJ, Xue S, Pei L, Vukusic B, Chery N, Wang Y, Wang YT, Niznik HB, Yu XM, Liu F. Dual regulation of NMDA receptor functions by direct protein-protein interactions with the dopamine D1 receptor. Cell 2002; 111(2):219-230.
92. Dampney RA, Horiuchi J, Tagawa T, Fontes MA, Potts PD, Polson JW. Medullary and supramedullary mechanisms regulating sympathetic vasomotor tone. Acta Physiol Scand 2003; 177(3):209-218.
93. Mifflin SW. What does the brain know about blood pressure? News Physiol Sci 2001; 16:266-271.
94. A receptor research. Synapse 1995; 21(3):189-274.
95. A receptors. Brain Res Rev 1999; 29(2-3):196-217.
96. Sasaki S, Nakata T, Kawasaki S, Hayashi J, Oguro M, Takeda K, Nakagawa M. Chronic central GABAergic stimulation attenuates hypothalamic hyperactivity and development of spontaneous hypertension in rats. J Cardiovasc Pharmacol 1990; 15(5):706-713.
97. A receptor binding in the amygdala and hypothalamus of spontaneously hypertensive rats. Brain Res Bull 1995; 36(1):57-61.
98. Shonis CA, Peano CA, Dillon GH, Waldrop TG. Cardiovascular responses to blockade of GABA synthesis in the hypothalamus of the spontaneously hypertensive rat. Brain Res Bull 1993; 31(5):493-499.
99. Liu F, Wan Q, Pristupa ZB, Yu XM, Wang YT, Niznik HB. Direct protein-protein coupling enables cross-talk between dopamine D5 and gamma-aminobutyric acid A receptors. Nature 2000; 403(6767):274-280.
100. Rivera A, Alberti I, Martin AB, Narvaez JA, de la Calle A, Moratalla R. Molecular phenotype of rat striatal neurons expressing the dopamine D5 receptor subtype. Eur J Neurosci 2002; 16(11):2049-2058.
101. 2+- sensitive GABA(A) currents in striatal cholinergic interneurons through a PKA/PP1 cascade. Neuron 1997; 19(5):1115-1126.
102. Thibonnier M, Coles P, Thibonnier A, Shoham M. The basic and clinical pharmacology of nonpeptide vasopressin receptor antagonists. Annu Rev Pharmacol Toxicol 2001; 41:175-202.
103. Johnston CI. Vasopressin in circulatory control and hypertension. J Hypertens 1985; 3(6):557-569.
104. Migita K, Hori N, Manako J, Saito R, Takano Y, Kamiya H. Effects of arginine-vasopressin on neuronal interaction from the area postrema to the nucleus tractus solitarii in rat brain slices. Neurosci Lett 1998; 256(1):45-48.
105. Andreatta-Van Leyen S, Averill DB, Ferrario CM. Cardiovascular actions of vasopressin at the ventrolateral medulla. Hypertension 1990; 15(2 Suppl): 1102-1106.
106. Thibonnier M, Coles P, Thibonnier A, Shoham M. Molecular pharmacology and modeling of vasopressin receptors. Prog Brain Res 2002; 139:179-196.
107. Bakris G, Bursztyn M, Gavras I, Bresnahan M, Gavras H. Role of vasopressin in essential hypertension: racial differences. J Hypertens 1997; 15(5):545-550.
108. Feng JJ, Arendshorst WJ. Enhanced renal vasoconstriction induced by vasopressin in SHR is mediated by V1 receptors. Am J Physiol 1996; 271(2 Pt 2):F304-F313.
109. Hasser EM, Cunningham JT, Sullivan MJ, Curtis KS, Blaine EH, Hay M. Area postrema and sympathetic nervous system effects of vasopressin and angiotensin II. Clin Exp Pharmacol Physiol 2000; 27(5-6):432-436.
110. Kubo T, Amano H, Misu Y. Caudal ventrolateral medulla. A region responsible for the mediation of vasopressin-induced presser responses. Naunyn Schmiedebergs Arch Pharmacol 1985; 328(4):365-372.
111. Aylwin ML, Horowitz JM, Bonham AC. Non-NMDA and NMDA receptors in the synaptic pathway between area postrema and nucleus tractus solitarius. Am J Physiol 1998; 275(4 Pt 2):H1236-H1246.
112. Yang Z, Coote JH. The influence of vasopressin on tonic activity of cardiovascular neurones in the ventrolateral medulla of the hypertensive rat. Auton Neurosci 2003; 104(2):83-87.
113. Schafer JA, Li L, Sun D. The collecting duct, dopamine and vasopressin-dependent hypertension. Acta Physiol Scand 2000; 168(1):239-244.
114. 2-adrenoceptors. J Pharmacol Exp Ther 2001; 298(3):1001-1006.
115. Freidinger RM, Pettibone DJ. Small molecule ligands for oxytocin and vasopressin receptors. Med Res Rev 1997; 17(1):1-16.
116. Dutil J, Moujahidine M, Lemieux C, Jankowski M, Gutkowska J, Deng AY. Chromosomal and comparative mapping of rat oxytocin, oxytocin receptor and vasopressin genes. Cytogenet Cell Genet 2001; 93(1-2):57-59.
117. Poulin P, Komulainen A, Takahashi Y, Pittman QJ. Enhanced presser responses to ICV vasopressin after pretreatment with oxytocin. Am J Physiol 1994; 266(2 Pt 2):R592-R598.
118. Diz DI, Jessup JA, Westwood BM, Bosch SM, Vinsant S, Gallagher PE, Averill DB. Angiotensin peptides as neurotransmitters/neuromodulators in the dorsomedial medulla. Clin Exp Pharmacol Physiol 2002; 29(5-6):473-482.
119. Richards EM, Raizada MK, Gelband CH, Sumners C. Angiotensin II type 1 receptor-modulated signaling pathways in neurons. Mol Neurobiol 1999; 19(1):25-41.
120. Campese VM. A new model of neurogenic hypertension caused by renal injury: pathophysiology and therapeutic implications. Clin Exp Nephrol 2003; 7(3):167-171.
121. Sved AF, Ito S, Sved JC. Brainstem mechanisms of hypertension: role of the rostral ventrolateral medulla. Curr Hypertens Rep 2003; 5(3):262-268.
122. Cochrane KL, Nathan MA. Presser systems involved in the maintenance of arterial pressure after lesions of the rostral ventrolateral medulla. J Auton Nerv Syst 1994; 46(1-2):9-18.
123. Ito S, Hiratsuka M, Komatsu K, Tsukamoto K, Kanmatsuse K, Sved AF. Ventrolateral medulla AT1 receptors support arterial pressure in Dahl salt-sensitive rats. Hypertension 2003; 41(3 Pt 2):744-750.
124. Head GA. Role of AT1 receptors in the central control of sympathetic vasomotor function. Clin Exp Pharmacol Physiol Suppl 1996; 3:S93-S98.
125. Blackburn RE, Demko AD, Hoffman GE, Stricker EM, Verbalis JG. Central oxytocin inhibition of angiotensin-induced salt appetite in rats. Am J Physiol 1992; 263(6 Pt 2):R1347-R1353.
126. Mosqueda-Garcia R, Yates K, O'Leary J, Inagami T. Cardiovascular and respiratory effects of endothelin in the ventrolateral medulla of the normotensive rat. Hypertension 1995; 26(2):263-271.